Data visualisation application speeds lead discovery

Published: 31-Aug-2010
Manufacturing Research & Development

Merck Millipore has new software for visualising GPCR and kinase activity

The Life Science division of Merck KGaA, Merck Millipore has introduced a software application for visualising GPCR (G-protein coupled receptors), as well as kinase activity.

The new Data Analysis and Report Tool (DART) creates an interactive map of target profiling assay results and enables drug researchers to make faster, more informed decisions.

‘Lead profiling often requires sifting through hundreds or even thousands of data points to pinpoint targets for further optimization studies,’ said Paul Wilhite, senior manager of eBusiness at Merck Millipore. ‘This new online tool provides a unique, information-rich interface so scientists can rapidly narrow their research and effectively collaborate with colleagues.’

The application projects each compound's activity profile onto a map depicting clusters of target protein families. This map provides scientists with immediate graphical insight into cross-target interactions to help drive structure-activity relationship (SAR) studies. The application is fully customisable. Data limits, sizing, colours, and target subclasses can be adjusted in seconds, thereby turning numerical data into a graphical display that can highlight biologically significant conclusions. Additionally, selected target information is dynamically populated and includes the gene symbol and aliases; links to bioinformatics content and recent publications; as well as links to appropriate Merck Millipore products.

Users of Merck Millipore's KinaseProfiler and GPCRProfiler screening services can upload their data directly into the DART tool or enter other datasets manually to take advantage of the software's analytical power and presentation-quality images.

See more

You may also like

Manufacturing

Pioneering Peptide-Builder debuts at UEA

Read more
Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  3. Abzena and Mabqi announce strategic partnership to offer integrated discovery through development solution This collaboration will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution
  4. Christian Mias to succeed Andreas Reisse as CEO of SCHOTT Pharma Executive with over 20 years of management experience to lead pharmaceutical packaging and delivery systems company

You may also like

Manufacturing

Pioneering Peptide-Builder debuts at UEA

Vapourtec kept it local with the first ever installation of their pioneering production Peptide-Builder system taking place at the University of East Anglia (UEA) in Norwich
Manufacturing

Moderna invests $140m to onshore drug product manufacturing and complete US end-to-end mRNA network

Moderna is expanding its Norwood, Massachusetts site to bring drug product manufacturing in-house, creating hundreds of biomanufacturing jobs and establishing full domestic, end-to-end production for its mRNA vaccines and therapeutics by 2027
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Manufacturing

GEA to showcase Rockwell Automation-Compatible GEA kytero 2000 Single-Use Separator at Automation Fair 2025

As a gold-level OEM member of the Rockwell PartnerNetwork™, GEA is strengthening its collaboration with Rockwell by offering full compatibility between the kytero® 2000 and Rockwell’s latest hardware and software suite
Sustainability

UK Invests £9.9m to turn recycled nuclear material into lead-212 cancer therapies

A new UK-wide programme will use recycled nuclear fuel to create sustainable lead-212 targeted alpha therapies, aiming to deliver next-generation precision cancer treatments for hard-to-treat tumours
Research & Development

OSE Immunotherapeutics gets positive IDMC recommendation to continue Phase III trial of Tedopi for lung cancer

The Independent Data Monitoring Committee has endorsed the ongoing pivotal Phase III ARTEMIA study evaluating Tedopi in HLA-A2–positive metastatic non-small cell lung cancer
Research & Development

American Cancer Society expands ACS ACTS programme to boost equity in cancer clinical trials nationwide

Leveraging trained specialists and AI-powered trial matching, the ACS ACTS programme helps patients, caregivers and providers navigate clinical trial options while addressing barriers to participation
Subscribe now